0001004878-13-000354.txt : 20131217
0001004878-13-000354.hdr.sgml : 20131217
20131216194333
ACCESSION NUMBER: 0001004878-13-000354
CONFORMED SUBMISSION TYPE: NT 10-K
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130930
FILED AS OF DATE: 20131217
DATE AS OF CHANGE: 20131216
EFFECTIVENESS DATE: 20131217
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CEL SCI CORP
CENTRAL INDEX KEY: 0000725363
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 840916344
STATE OF INCORPORATION: CO
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: NT 10-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11889
FILM NUMBER: 131280158
BUSINESS ADDRESS:
STREET 1: 8229 BOONE BLVD .
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
BUSINESS PHONE: 7035069460
MAIL ADDRESS:
STREET 1: 8229 BOONE BLVD.
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
FORMER COMPANY:
FORMER CONFORMED NAME: INTERLEUKIN 2 INC
DATE OF NAME CHANGE: 19880317
NT 10-K
1
ntsept201310kdec-13.txt
12B-25 FOR SEPT 2013 10-K
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SEC File Number ___________
CUSIP Number _____________
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One):
[X] Form 10-K [ ]Form 20-F [ ]Form 11-K [ ]Form 10-Q [ ]Form 10-D [ ]Form N-SAR
For Period Ended: September 30, 2013
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 10-Q
For the Transition Period Ended: __________
---------------------------------
Nothing in this Form shall be construed to imply that the Commission has
verified any information contained herein.
---------------------------------
Part I - Registrant Information
---------------------------------
Full Name of Registrant: CEL-SCI CORPORATION
Former Name if Applicable: N/A
Address of Principal Executive Office (Street and Number)
8229 Boone Blvd. #802
City, State and Zip Code
Vienna, VA 22182
---------------------------------
Part II - Rules 12b-25(b) and (c)
---------------------------------
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed.
(Check box if appropriate)
[X] a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, or transition report
or portion thereof will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject quarterly report
or transition report on Form l0-Q or portion thereof will be filed on
or before the fifth calendar day following the prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
---------------------------------
Part III - Narrative
---------------------------------
State below in reasonable detail the reasons why the Form 10-K, 20-F,
11-K, 10-Q, or N-SAR, or the transition report or portion thereof could not be
filed within the prescribed time period.
The Company did not complete its financial statements for the year ended
August 31, 2013 in sufficient time so as to allow the filing of the report by
November 29, 2013.
---------------------------------
Part IV - Other Information
---------------------------------
(1) Name and telephone number of person to contact in regard to this
notification
William T. Hart (303) 839-0061
----------------- ----- -------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding l2 months (or for such
shorter period that the registrant was required to file such reports) been
filed? If answer is no, identify report(s). [X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof? [ ] Yes [X] No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
CEL-SCI CORPORATION
----------------------------------
(Name of Registrant as specified in charter)
has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: December 16, 2013 By: /s/ Patricia B. Prichep
----------------------------
Patricia B. Prichep,
Senior Vice President of Operations
ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001).